nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—CYP3A4—Temozolomide—brain cancer	0.0713	0.342	CbGbCtD
Sirolimus—CYP3A4—Lomustine—brain cancer	0.0606	0.291	CbGbCtD
Sirolimus—CYP3A5—Etoposide—brain cancer	0.0376	0.18	CbGbCtD
Sirolimus—ABCB1—Etoposide—brain cancer	0.0245	0.117	CbGbCtD
Sirolimus—CYP3A4—Etoposide—brain cancer	0.0147	0.0702	CbGbCtD
Sirolimus—EIF4E—telencephalon—brain cancer	0.00694	0.0562	CbGeAlD
Sirolimus—EIF4E—gonad—brain cancer	0.0058	0.0469	CbGeAlD
Sirolimus—MTOR—blood vessel—brain cancer	0.00554	0.0448	CbGeAlD
Sirolimus—MTOR—hindbrain—brain cancer	0.00528	0.0427	CbGeAlD
Sirolimus—EIF4E—endocrine gland—brain cancer	0.00438	0.0354	CbGeAlD
Sirolimus—EIF4E—head—brain cancer	0.00432	0.035	CbGeAlD
Sirolimus—SLC47A1—hindbrain—brain cancer	0.00408	0.033	CbGeAlD
Sirolimus—EIF4E—central nervous system—brain cancer	0.00395	0.0319	CbGeAlD
Sirolimus—FGF2—pituitary gland—brain cancer	0.00345	0.0279	CbGeAlD
Sirolimus—FGF2—medulla oblongata—brain cancer	0.00333	0.0269	CbGeAlD
Sirolimus—EIF4E—brain—brain cancer	0.00313	0.0253	CbGeAlD
Sirolimus—FGF2—midbrain—brain cancer	0.00304	0.0246	CbGeAlD
Sirolimus—MTOR—brainstem—brain cancer	0.00303	0.0245	CbGeAlD
Sirolimus—FGF2—spinal cord—brain cancer	0.00297	0.024	CbGeAlD
Sirolimus—MTOR—telencephalon—brain cancer	0.00269	0.0217	CbGeAlD
Sirolimus—FKBP1A—telencephalon—brain cancer	0.00242	0.0195	CbGeAlD
Sirolimus—FGF2—cerebellum—brain cancer	0.00235	0.019	CbGeAlD
Sirolimus—SLC47A1—brainstem—brain cancer	0.00234	0.0189	CbGeAlD
Sirolimus—MTOR—gonad—brain cancer	0.00224	0.0181	CbGeAlD
Sirolimus—MTOR—pituitary gland—brain cancer	0.00219	0.0177	CbGeAlD
Sirolimus—FKBP1A—gonad—brain cancer	0.00202	0.0163	CbGeAlD
Sirolimus—FKBP1A—pituitary gland—brain cancer	0.00197	0.0159	CbGeAlD
Sirolimus—FGF2—brain—brain cancer	0.00191	0.0155	CbGeAlD
Sirolimus—FKBP1A—medulla oblongata—brain cancer	0.0019	0.0154	CbGeAlD
Sirolimus—CYP3A7—endocrine gland—brain cancer	0.00189	0.0153	CbGeAlD
Sirolimus—MTOR—spinal cord—brain cancer	0.00188	0.0152	CbGeAlD
Sirolimus—FKBP1A—midbrain—brain cancer	0.00174	0.014	CbGeAlD
Sirolimus—SLC47A1—gonad—brain cancer	0.00173	0.014	CbGeAlD
Sirolimus—MTOR—endocrine gland—brain cancer	0.00169	0.0137	CbGeAlD
Sirolimus—FKBP1A—spinal cord—brain cancer	0.00169	0.0137	CbGeAlD
Sirolimus—SLC47A1—pituitary gland—brain cancer	0.00169	0.0137	CbGeAlD
Sirolimus—MTOR—head—brain cancer	0.00167	0.0135	CbGeAlD
Sirolimus—SLC47A1—medulla oblongata—brain cancer	0.00163	0.0132	CbGeAlD
Sirolimus—MTOR—central nervous system—brain cancer	0.00153	0.0124	CbGeAlD
Sirolimus—FKBP1A—endocrine gland—brain cancer	0.00152	0.0123	CbGeAlD
Sirolimus—FKBP1A—head—brain cancer	0.0015	0.0122	CbGeAlD
Sirolimus—MTOR—cerebellum—brain cancer	0.00149	0.0121	CbGeAlD
Sirolimus—SLC47A1—spinal cord—brain cancer	0.00146	0.0118	CbGeAlD
Sirolimus—FKBP1A—central nervous system—brain cancer	0.00137	0.0111	CbGeAlD
Sirolimus—FKBP1A—cerebellum—brain cancer	0.00134	0.0109	CbGeAlD
Sirolimus—SLC47A1—endocrine gland—brain cancer	0.00131	0.0106	CbGeAlD
Sirolimus—SLCO1B1—endocrine gland—brain cancer	0.00129	0.0105	CbGeAlD
Sirolimus—SLC47A1—head—brain cancer	0.00129	0.0105	CbGeAlD
Sirolimus—MTOR—brain—brain cancer	0.00121	0.00981	CbGeAlD
Sirolimus—SLC47A1—central nervous system—brain cancer	0.00118	0.00955	CbGeAlD
Sirolimus—SLC47A1—cerebellum—brain cancer	0.00115	0.00933	CbGeAlD
Sirolimus—ABCB1—blood vessel—brain cancer	0.00115	0.00932	CbGeAlD
Sirolimus—FKBP1A—brain—brain cancer	0.00109	0.00882	CbGeAlD
Sirolimus—SLC47A1—brain—brain cancer	0.000937	0.00758	CbGeAlD
Sirolimus—CYP3A5—endocrine gland—brain cancer	0.000664	0.00537	CbGeAlD
Sirolimus—Angiopathy—Hydroxyurea—brain cancer	0.000619	0.00163	CcSEcCtD
Sirolimus—Upper respiratory tract infection—Temozolomide—brain cancer	0.000619	0.00163	CcSEcCtD
Sirolimus—Pneumonia—Carmustine—brain cancer	0.000618	0.00163	CcSEcCtD
Sirolimus—Shock—Procarbazine—brain cancer	0.000616	0.00162	CcSEcCtD
Sirolimus—Pollakiuria—Temozolomide—brain cancer	0.000615	0.00162	CcSEcCtD
Sirolimus—Erectile dysfunction—Temozolomide—brain cancer	0.000613	0.00162	CcSEcCtD
Sirolimus—Thrombocytopenia—Procarbazine—brain cancer	0.000613	0.00162	CcSEcCtD
Sirolimus—Chills—Hydroxyurea—brain cancer	0.000612	0.00161	CcSEcCtD
Sirolimus—Tachycardia—Procarbazine—brain cancer	0.000611	0.00161	CcSEcCtD
Sirolimus—Weight increased—Temozolomide—brain cancer	0.000606	0.0016	CcSEcCtD
Sirolimus—Hyperhidrosis—Procarbazine—brain cancer	0.000605	0.0016	CcSEcCtD
Sirolimus—Weight decreased—Temozolomide—brain cancer	0.000602	0.00159	CcSEcCtD
Sirolimus—Neuropathy peripheral—Carmustine—brain cancer	0.000602	0.00159	CcSEcCtD
Sirolimus—Hyperglycaemia—Temozolomide—brain cancer	0.000601	0.00158	CcSEcCtD
Sirolimus—Stomatitis—Carmustine—brain cancer	0.000599	0.00158	CcSEcCtD
Sirolimus—Urinary tract infection—Carmustine—brain cancer	0.000597	0.00157	CcSEcCtD
Sirolimus—Pneumonia—Temozolomide—brain cancer	0.000597	0.00157	CcSEcCtD
Sirolimus—Anorexia—Procarbazine—brain cancer	0.000597	0.00157	CcSEcCtD
Sirolimus—Infestation NOS—Temozolomide—brain cancer	0.000594	0.00156	CcSEcCtD
Sirolimus—Infestation—Temozolomide—brain cancer	0.000594	0.00156	CcSEcCtD
Sirolimus—Nausea—Lomustine—brain cancer	0.000586	0.00154	CcSEcCtD
Sirolimus—Hypotension—Procarbazine—brain cancer	0.000585	0.00154	CcSEcCtD
Sirolimus—Neuropathy peripheral—Temozolomide—brain cancer	0.000582	0.00153	CcSEcCtD
Sirolimus—Stomatitis—Temozolomide—brain cancer	0.000579	0.00153	CcSEcCtD
Sirolimus—Urinary tract infection—Temozolomide—brain cancer	0.000577	0.00152	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Procarbazine—brain cancer	0.00057	0.0015	CcSEcCtD
Sirolimus—Insomnia—Procarbazine—brain cancer	0.000566	0.00149	CcSEcCtD
Sirolimus—Paraesthesia—Procarbazine—brain cancer	0.000562	0.00148	CcSEcCtD
Sirolimus—Hepatobiliary disease—Temozolomide—brain cancer	0.000561	0.00148	CcSEcCtD
Sirolimus—ABCB1—telencephalon—brain cancer	0.000559	0.00452	CbGeAlD
Sirolimus—Sinusitis—Temozolomide—brain cancer	0.000557	0.00147	CcSEcCtD
Sirolimus—Somnolence—Procarbazine—brain cancer	0.000557	0.00147	CcSEcCtD
Sirolimus—Haemoglobin—Carmustine—brain cancer	0.000554	0.00146	CcSEcCtD
Sirolimus—Haemorrhage—Carmustine—brain cancer	0.000551	0.00145	CcSEcCtD
Sirolimus—Ill-defined disorder—Hydroxyurea—brain cancer	0.000551	0.00145	CcSEcCtD
Sirolimus—Anaemia—Hydroxyurea—brain cancer	0.000549	0.00145	CcSEcCtD
Sirolimus—Hypoaesthesia—Carmustine—brain cancer	0.000549	0.00145	CcSEcCtD
Sirolimus—Hallucination—Carmustine—brain cancer	0.000549	0.00145	CcSEcCtD
Sirolimus—Decreased appetite—Procarbazine—brain cancer	0.000544	0.00143	CcSEcCtD
Sirolimus—Alanine aminotransferase increased—Etoposide—brain cancer	0.000544	0.00143	CcSEcCtD
Sirolimus—Oedema peripheral—Carmustine—brain cancer	0.000543	0.00143	CcSEcCtD
Sirolimus—Connective tissue disorder—Carmustine—brain cancer	0.000542	0.00143	CcSEcCtD
Sirolimus—Haemoglobin—Temozolomide—brain cancer	0.000536	0.00141	CcSEcCtD
Sirolimus—Malaise—Hydroxyurea—brain cancer	0.000535	0.00141	CcSEcCtD
Sirolimus—Pain—Procarbazine—brain cancer	0.000535	0.00141	CcSEcCtD
Sirolimus—Constipation—Procarbazine—brain cancer	0.000535	0.00141	CcSEcCtD
Sirolimus—Haemorrhage—Temozolomide—brain cancer	0.000533	0.0014	CcSEcCtD
Sirolimus—Dysphagia—Etoposide—brain cancer	0.000533	0.0014	CcSEcCtD
Sirolimus—Leukopenia—Hydroxyurea—brain cancer	0.000531	0.0014	CcSEcCtD
Sirolimus—Visual impairment—Carmustine—brain cancer	0.000531	0.0014	CcSEcCtD
Sirolimus—Hypoaesthesia—Temozolomide—brain cancer	0.00053	0.0014	CcSEcCtD
Sirolimus—Hallucination—Temozolomide—brain cancer	0.00053	0.0014	CcSEcCtD
Sirolimus—Pharyngitis—Temozolomide—brain cancer	0.000529	0.00139	CcSEcCtD
Sirolimus—Urinary tract disorder—Temozolomide—brain cancer	0.000526	0.00139	CcSEcCtD
Sirolimus—Oedema peripheral—Temozolomide—brain cancer	0.000525	0.00138	CcSEcCtD
Sirolimus—Connective tissue disorder—Temozolomide—brain cancer	0.000524	0.00138	CcSEcCtD
Sirolimus—Urethral disorder—Temozolomide—brain cancer	0.000522	0.00138	CcSEcCtD
Sirolimus—Feeling abnormal—Procarbazine—brain cancer	0.000516	0.00136	CcSEcCtD
Sirolimus—Visual impairment—Temozolomide—brain cancer	0.000513	0.00135	CcSEcCtD
Sirolimus—Gastrointestinal pain—Procarbazine—brain cancer	0.000512	0.00135	CcSEcCtD
Sirolimus—Pancytopenia—Etoposide—brain cancer	0.000506	0.00133	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—brain cancer	0.000502	0.00132	CcSEcCtD
Sirolimus—Discomfort—Hydroxyurea—brain cancer	0.000499	0.00132	CcSEcCtD
Sirolimus—Neutropenia—Etoposide—brain cancer	0.000498	0.00131	CcSEcCtD
Sirolimus—CYP3A4—endocrine gland—brain cancer	0.000498	0.00403	CbGeAlD
Sirolimus—Tinnitus—Temozolomide—brain cancer	0.000497	0.00131	CcSEcCtD
Sirolimus—Body temperature increased—Procarbazine—brain cancer	0.000495	0.0013	CcSEcCtD
Sirolimus—Abdominal pain—Procarbazine—brain cancer	0.000495	0.0013	CcSEcCtD
Sirolimus—Cardiac disorder—Temozolomide—brain cancer	0.000495	0.0013	CcSEcCtD
Sirolimus—Oedema—Hydroxyurea—brain cancer	0.000485	0.00128	CcSEcCtD
Sirolimus—Angiopathy—Temozolomide—brain cancer	0.000483	0.00127	CcSEcCtD
Sirolimus—Infection—Hydroxyurea—brain cancer	0.000481	0.00127	CcSEcCtD
Sirolimus—Immune system disorder—Temozolomide—brain cancer	0.000481	0.00127	CcSEcCtD
Sirolimus—Mediastinal disorder—Temozolomide—brain cancer	0.00048	0.00127	CcSEcCtD
Sirolimus—Malnutrition—Carmustine—brain cancer	0.00048	0.00127	CcSEcCtD
Sirolimus—Chills—Temozolomide—brain cancer	0.000478	0.00126	CcSEcCtD
Sirolimus—Pneumonia—Etoposide—brain cancer	0.000478	0.00126	CcSEcCtD
Sirolimus—Nervous system disorder—Hydroxyurea—brain cancer	0.000475	0.00125	CcSEcCtD
Sirolimus—Infestation NOS—Etoposide—brain cancer	0.000475	0.00125	CcSEcCtD
Sirolimus—Infestation—Etoposide—brain cancer	0.000475	0.00125	CcSEcCtD
Sirolimus—Thrombocytopenia—Hydroxyurea—brain cancer	0.000474	0.00125	CcSEcCtD
Sirolimus—Skin disorder—Hydroxyurea—brain cancer	0.000471	0.00124	CcSEcCtD
Sirolimus—ABCB1—gonad—brain cancer	0.000467	0.00377	CbGeAlD
Sirolimus—Neuropathy peripheral—Etoposide—brain cancer	0.000466	0.00123	CcSEcCtD
Sirolimus—Back pain—Carmustine—brain cancer	0.000464	0.00122	CcSEcCtD
Sirolimus—Malnutrition—Temozolomide—brain cancer	0.000464	0.00122	CcSEcCtD
Sirolimus—Stomatitis—Etoposide—brain cancer	0.000463	0.00122	CcSEcCtD
Sirolimus—Anorexia—Hydroxyurea—brain cancer	0.000462	0.00122	CcSEcCtD
Sirolimus—Hypersensitivity—Procarbazine—brain cancer	0.000461	0.00122	CcSEcCtD
Sirolimus—ABCB1—pituitary gland—brain cancer	0.000455	0.00368	CbGeAlD
Sirolimus—Tremor—Carmustine—brain cancer	0.00045	0.00119	CcSEcCtD
Sirolimus—Asthenia—Procarbazine—brain cancer	0.000449	0.00118	CcSEcCtD
Sirolimus—Hepatobiliary disease—Etoposide—brain cancer	0.000449	0.00118	CcSEcCtD
Sirolimus—CYP3A4—central nervous system—brain cancer	0.000449	0.00363	CbGeAlD
Sirolimus—Back pain—Temozolomide—brain cancer	0.000449	0.00118	CcSEcCtD
Sirolimus—Anaemia—Carmustine—brain cancer	0.000444	0.00117	CcSEcCtD
Sirolimus—Pruritus—Procarbazine—brain cancer	0.000443	0.00117	CcSEcCtD
Sirolimus—Agitation—Carmustine—brain cancer	0.000441	0.00116	CcSEcCtD
Sirolimus—ABCB1—medulla oblongata—brain cancer	0.000439	0.00355	CbGeAlD
Sirolimus—Tremor—Temozolomide—brain cancer	0.000435	0.00115	CcSEcCtD
Sirolimus—Dyspnoea—Hydroxyurea—brain cancer	0.000432	0.00114	CcSEcCtD
Sirolimus—Somnolence—Hydroxyurea—brain cancer	0.000431	0.00114	CcSEcCtD
Sirolimus—Ill-defined disorder—Temozolomide—brain cancer	0.00043	0.00113	CcSEcCtD
Sirolimus—Leukopenia—Carmustine—brain cancer	0.00043	0.00113	CcSEcCtD
Sirolimus—Anaemia—Temozolomide—brain cancer	0.000429	0.00113	CcSEcCtD
Sirolimus—Diarrhoea—Procarbazine—brain cancer	0.000428	0.00113	CcSEcCtD
Sirolimus—Dyspepsia—Hydroxyurea—brain cancer	0.000427	0.00112	CcSEcCtD
Sirolimus—Agitation—Temozolomide—brain cancer	0.000426	0.00112	CcSEcCtD
Sirolimus—Hypoaesthesia—Etoposide—brain cancer	0.000424	0.00112	CcSEcCtD
Sirolimus—Angioedema—Temozolomide—brain cancer	0.000424	0.00112	CcSEcCtD
Sirolimus—Decreased appetite—Hydroxyurea—brain cancer	0.000421	0.00111	CcSEcCtD
Sirolimus—Urinary tract disorder—Etoposide—brain cancer	0.000421	0.00111	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.000418	0.0011	CcSEcCtD
Sirolimus—Malaise—Temozolomide—brain cancer	0.000418	0.0011	CcSEcCtD
Sirolimus—Urethral disorder—Etoposide—brain cancer	0.000418	0.0011	CcSEcCtD
Sirolimus—Leukopenia—Temozolomide—brain cancer	0.000415	0.00109	CcSEcCtD
Sirolimus—Hypertension—Carmustine—brain cancer	0.000414	0.00109	CcSEcCtD
Sirolimus—Pain—Hydroxyurea—brain cancer	0.000414	0.00109	CcSEcCtD
Sirolimus—Constipation—Hydroxyurea—brain cancer	0.000414	0.00109	CcSEcCtD
Sirolimus—Dizziness—Procarbazine—brain cancer	0.000414	0.00109	CcSEcCtD
Sirolimus—Palpitations—Temozolomide—brain cancer	0.00041	0.00108	CcSEcCtD
Sirolimus—Myalgia—Carmustine—brain cancer	0.000409	0.00108	CcSEcCtD
Sirolimus—Chest pain—Carmustine—brain cancer	0.000409	0.00108	CcSEcCtD
Sirolimus—Anxiety—Carmustine—brain cancer	0.000407	0.00107	CcSEcCtD
Sirolimus—Cough—Temozolomide—brain cancer	0.000405	0.00107	CcSEcCtD
Sirolimus—ABCB1—midbrain—brain cancer	0.000401	0.00325	CbGeAlD
Sirolimus—Hypertension—Temozolomide—brain cancer	0.0004	0.00106	CcSEcCtD
Sirolimus—Feeling abnormal—Hydroxyurea—brain cancer	0.000399	0.00105	CcSEcCtD
Sirolimus—Vomiting—Procarbazine—brain cancer	0.000398	0.00105	CcSEcCtD
Sirolimus—Cardiac disorder—Etoposide—brain cancer	0.000396	0.00104	CcSEcCtD
Sirolimus—Confusional state—Carmustine—brain cancer	0.000395	0.00104	CcSEcCtD
Sirolimus—Arthralgia—Temozolomide—brain cancer	0.000395	0.00104	CcSEcCtD
Sirolimus—Myalgia—Temozolomide—brain cancer	0.000395	0.00104	CcSEcCtD
Sirolimus—Rash—Procarbazine—brain cancer	0.000395	0.00104	CcSEcCtD
Sirolimus—Dermatitis—Procarbazine—brain cancer	0.000394	0.00104	CcSEcCtD
Sirolimus—Anxiety—Temozolomide—brain cancer	0.000394	0.00104	CcSEcCtD
Sirolimus—Headache—Procarbazine—brain cancer	0.000392	0.00103	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—brain cancer	0.000392	0.00103	CcSEcCtD
Sirolimus—Oedema—Carmustine—brain cancer	0.000392	0.00103	CcSEcCtD
Sirolimus—ABCB1—spinal cord—brain cancer	0.000392	0.00317	CbGeAlD
Sirolimus—Discomfort—Temozolomide—brain cancer	0.00039	0.00103	CcSEcCtD
Sirolimus—Infection—Carmustine—brain cancer	0.000389	0.00103	CcSEcCtD
Sirolimus—Angiopathy—Etoposide—brain cancer	0.000387	0.00102	CcSEcCtD
Sirolimus—Immune system disorder—Etoposide—brain cancer	0.000385	0.00102	CcSEcCtD
Sirolimus—Mediastinal disorder—Etoposide—brain cancer	0.000384	0.00101	CcSEcCtD
Sirolimus—Thrombocytopenia—Carmustine—brain cancer	0.000384	0.00101	CcSEcCtD
Sirolimus—Body temperature increased—Hydroxyurea—brain cancer	0.000383	0.00101	CcSEcCtD
Sirolimus—Chills—Etoposide—brain cancer	0.000383	0.00101	CcSEcCtD
Sirolimus—Tachycardia—Carmustine—brain cancer	0.000382	0.00101	CcSEcCtD
Sirolimus—Confusional state—Temozolomide—brain cancer	0.000382	0.00101	CcSEcCtD
Sirolimus—Anaphylactic shock—Temozolomide—brain cancer	0.000379	0.000998	CcSEcCtD
Sirolimus—Oedema—Temozolomide—brain cancer	0.000379	0.000998	CcSEcCtD
Sirolimus—Infection—Temozolomide—brain cancer	0.000376	0.000991	CcSEcCtD
Sirolimus—Anorexia—Carmustine—brain cancer	0.000373	0.000984	CcSEcCtD
Sirolimus—Nausea—Procarbazine—brain cancer	0.000372	0.00098	CcSEcCtD
Sirolimus—Nervous system disorder—Temozolomide—brain cancer	0.000371	0.000979	CcSEcCtD
Sirolimus—Thrombocytopenia—Temozolomide—brain cancer	0.000371	0.000977	CcSEcCtD
Sirolimus—Skin disorder—Temozolomide—brain cancer	0.000368	0.000969	CcSEcCtD
Sirolimus—Hypotension—Carmustine—brain cancer	0.000366	0.000965	CcSEcCtD
Sirolimus—Hyperhidrosis—Temozolomide—brain cancer	0.000366	0.000965	CcSEcCtD
Sirolimus—Anorexia—Temozolomide—brain cancer	0.000361	0.000951	CcSEcCtD
Sirolimus—Back pain—Etoposide—brain cancer	0.000359	0.000946	CcSEcCtD
Sirolimus—Hypersensitivity—Hydroxyurea—brain cancer	0.000357	0.000941	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Carmustine—brain cancer	0.000357	0.000941	CcSEcCtD
Sirolimus—Muscle spasms—Etoposide—brain cancer	0.000357	0.000941	CcSEcCtD
Sirolimus—Insomnia—Carmustine—brain cancer	0.000354	0.000934	CcSEcCtD
Sirolimus—ABCB1—endocrine gland—brain cancer	0.000353	0.00285	CbGeAlD
Sirolimus—Paraesthesia—Carmustine—brain cancer	0.000352	0.000927	CcSEcCtD
Sirolimus—Dyspnoea—Carmustine—brain cancer	0.000349	0.000921	CcSEcCtD
Sirolimus—Somnolence—Carmustine—brain cancer	0.000348	0.000918	CcSEcCtD
Sirolimus—ABCB1—head—brain cancer	0.000348	0.00282	CbGeAlD
Sirolimus—Asthenia—Hydroxyurea—brain cancer	0.000348	0.000917	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Temozolomide—brain cancer	0.000345	0.000909	CcSEcCtD
Sirolimus—Ill-defined disorder—Etoposide—brain cancer	0.000344	0.000908	CcSEcCtD
Sirolimus—Anaemia—Etoposide—brain cancer	0.000343	0.000904	CcSEcCtD
Sirolimus—Insomnia—Temozolomide—brain cancer	0.000342	0.000903	CcSEcCtD
Sirolimus—Decreased appetite—Carmustine—brain cancer	0.000341	0.000898	CcSEcCtD
Sirolimus—Paraesthesia—Temozolomide—brain cancer	0.00034	0.000896	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Carmustine—brain cancer	0.000338	0.000892	CcSEcCtD
Sirolimus—Dyspnoea—Temozolomide—brain cancer	0.000337	0.00089	CcSEcCtD
Sirolimus—Somnolence—Temozolomide—brain cancer	0.000337	0.000887	CcSEcCtD
Sirolimus—Pain—Carmustine—brain cancer	0.000335	0.000883	CcSEcCtD
Sirolimus—Constipation—Carmustine—brain cancer	0.000335	0.000883	CcSEcCtD
Sirolimus—Malaise—Etoposide—brain cancer	0.000335	0.000882	CcSEcCtD
Sirolimus—Dyspepsia—Temozolomide—brain cancer	0.000333	0.000878	CcSEcCtD
Sirolimus—Leukopenia—Etoposide—brain cancer	0.000332	0.000876	CcSEcCtD
Sirolimus—Diarrhoea—Hydroxyurea—brain cancer	0.000332	0.000874	CcSEcCtD
Sirolimus—Decreased appetite—Temozolomide—brain cancer	0.000329	0.000868	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Temozolomide—brain cancer	0.000327	0.000862	CcSEcCtD
Sirolimus—Loss of consciousness—Etoposide—brain cancer	0.000326	0.00086	CcSEcCtD
Sirolimus—Cough—Etoposide—brain cancer	0.000324	0.000854	CcSEcCtD
Sirolimus—Pain—Temozolomide—brain cancer	0.000324	0.000853	CcSEcCtD
Sirolimus—Constipation—Temozolomide—brain cancer	0.000324	0.000853	CcSEcCtD
Sirolimus—Feeling abnormal—Carmustine—brain cancer	0.000323	0.000851	CcSEcCtD
Sirolimus—Hypertension—Etoposide—brain cancer	0.00032	0.000845	CcSEcCtD
Sirolimus—Dizziness—Hydroxyurea—brain cancer	0.00032	0.000845	CcSEcCtD
Sirolimus—Gastrointestinal pain—Carmustine—brain cancer	0.00032	0.000844	CcSEcCtD
Sirolimus—ABCB1—central nervous system—brain cancer	0.000318	0.00257	CbGeAlD
Sirolimus—Chest pain—Etoposide—brain cancer	0.000316	0.000833	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Etoposide—brain cancer	0.000314	0.000827	CcSEcCtD
Sirolimus—Discomfort—Etoposide—brain cancer	0.000312	0.000823	CcSEcCtD
Sirolimus—Feeling abnormal—Temozolomide—brain cancer	0.000312	0.000822	CcSEcCtD
Sirolimus—ABCB1—cerebellum—brain cancer	0.000311	0.00251	CbGeAlD
Sirolimus—Abdominal pain—Carmustine—brain cancer	0.00031	0.000816	CcSEcCtD
Sirolimus—Body temperature increased—Carmustine—brain cancer	0.00031	0.000816	CcSEcCtD
Sirolimus—Gastrointestinal pain—Temozolomide—brain cancer	0.00031	0.000816	CcSEcCtD
Sirolimus—Vomiting—Hydroxyurea—brain cancer	0.000308	0.000812	CcSEcCtD
Sirolimus—Rash—Hydroxyurea—brain cancer	0.000306	0.000805	CcSEcCtD
Sirolimus—Confusional state—Etoposide—brain cancer	0.000305	0.000805	CcSEcCtD
Sirolimus—Dermatitis—Hydroxyurea—brain cancer	0.000305	0.000805	CcSEcCtD
Sirolimus—Headache—Hydroxyurea—brain cancer	0.000304	0.0008	CcSEcCtD
Sirolimus—Anaphylactic shock—Etoposide—brain cancer	0.000303	0.000799	CcSEcCtD
Sirolimus—Infection—Etoposide—brain cancer	0.000301	0.000793	CcSEcCtD
Sirolimus—Body temperature increased—Temozolomide—brain cancer	0.000299	0.000789	CcSEcCtD
Sirolimus—Abdominal pain—Temozolomide—brain cancer	0.000299	0.000789	CcSEcCtD
Sirolimus—Thrombocytopenia—Etoposide—brain cancer	0.000297	0.000782	CcSEcCtD
Sirolimus—Tachycardia—Etoposide—brain cancer	0.000296	0.000779	CcSEcCtD
Sirolimus—Skin disorder—Etoposide—brain cancer	0.000294	0.000776	CcSEcCtD
Sirolimus—Hyperhidrosis—Etoposide—brain cancer	0.000293	0.000772	CcSEcCtD
Sirolimus—Anorexia—Etoposide—brain cancer	0.000289	0.000761	CcSEcCtD
Sirolimus—Hypersensitivity—Carmustine—brain cancer	0.000289	0.000761	CcSEcCtD
Sirolimus—Nausea—Hydroxyurea—brain cancer	0.000288	0.000759	CcSEcCtD
Sirolimus—Hypotension—Etoposide—brain cancer	0.000283	0.000746	CcSEcCtD
Sirolimus—Asthenia—Carmustine—brain cancer	0.000281	0.000741	CcSEcCtD
Sirolimus—Hypersensitivity—Temozolomide—brain cancer	0.000279	0.000735	CcSEcCtD
Sirolimus—Paraesthesia—Etoposide—brain cancer	0.000272	0.000717	CcSEcCtD
Sirolimus—Asthenia—Temozolomide—brain cancer	0.000272	0.000716	CcSEcCtD
Sirolimus—Dyspnoea—Etoposide—brain cancer	0.00027	0.000712	CcSEcCtD
Sirolimus—Somnolence—Etoposide—brain cancer	0.000269	0.00071	CcSEcCtD
Sirolimus—Diarrhoea—Carmustine—brain cancer	0.000268	0.000707	CcSEcCtD
Sirolimus—Pruritus—Temozolomide—brain cancer	0.000268	0.000706	CcSEcCtD
Sirolimus—Decreased appetite—Etoposide—brain cancer	0.000263	0.000694	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Etoposide—brain cancer	0.000262	0.000689	CcSEcCtD
Sirolimus—Dizziness—Carmustine—brain cancer	0.000259	0.000683	CcSEcCtD
Sirolimus—Pain—Etoposide—brain cancer	0.000259	0.000683	CcSEcCtD
Sirolimus—Constipation—Etoposide—brain cancer	0.000259	0.000683	CcSEcCtD
Sirolimus—Diarrhoea—Temozolomide—brain cancer	0.000259	0.000683	CcSEcCtD
Sirolimus—ABCB1—brain—brain cancer	0.000252	0.00204	CbGeAlD
Sirolimus—Dizziness—Temozolomide—brain cancer	0.00025	0.00066	CcSEcCtD
Sirolimus—Feeling abnormal—Etoposide—brain cancer	0.00025	0.000658	CcSEcCtD
Sirolimus—Vomiting—Carmustine—brain cancer	0.000249	0.000657	CcSEcCtD
Sirolimus—Gastrointestinal pain—Etoposide—brain cancer	0.000248	0.000653	CcSEcCtD
Sirolimus—Rash—Carmustine—brain cancer	0.000247	0.000651	CcSEcCtD
Sirolimus—Dermatitis—Carmustine—brain cancer	0.000247	0.000651	CcSEcCtD
Sirolimus—Headache—Carmustine—brain cancer	0.000245	0.000647	CcSEcCtD
Sirolimus—Vomiting—Temozolomide—brain cancer	0.000241	0.000635	CcSEcCtD
Sirolimus—Body temperature increased—Etoposide—brain cancer	0.000239	0.000631	CcSEcCtD
Sirolimus—Abdominal pain—Etoposide—brain cancer	0.000239	0.000631	CcSEcCtD
Sirolimus—Rash—Temozolomide—brain cancer	0.000239	0.000629	CcSEcCtD
Sirolimus—Dermatitis—Temozolomide—brain cancer	0.000238	0.000629	CcSEcCtD
Sirolimus—Headache—Temozolomide—brain cancer	0.000237	0.000625	CcSEcCtD
Sirolimus—Nausea—Carmustine—brain cancer	0.000233	0.000613	CcSEcCtD
Sirolimus—Nausea—Temozolomide—brain cancer	0.000225	0.000593	CcSEcCtD
Sirolimus—Hypersensitivity—Etoposide—brain cancer	0.000223	0.000588	CcSEcCtD
Sirolimus—Asthenia—Etoposide—brain cancer	0.000217	0.000573	CcSEcCtD
Sirolimus—Pruritus—Etoposide—brain cancer	0.000214	0.000565	CcSEcCtD
Sirolimus—Diarrhoea—Etoposide—brain cancer	0.000207	0.000546	CcSEcCtD
Sirolimus—Dizziness—Etoposide—brain cancer	0.0002	0.000528	CcSEcCtD
Sirolimus—Vomiting—Etoposide—brain cancer	0.000193	0.000508	CcSEcCtD
Sirolimus—Rash—Etoposide—brain cancer	0.000191	0.000504	CcSEcCtD
Sirolimus—Dermatitis—Etoposide—brain cancer	0.000191	0.000503	CcSEcCtD
Sirolimus—Headache—Etoposide—brain cancer	0.00019	0.0005	CcSEcCtD
Sirolimus—Nausea—Etoposide—brain cancer	0.00018	0.000474	CcSEcCtD
Sirolimus—MTOR—Signaling by PDGF—STAT3—brain cancer	9.63e-05	0.000334	CbGpPWpGaD
Sirolimus—MTOR—EGF/EGFR Signaling Pathway—EGFR—brain cancer	9.6e-05	0.000333	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—EGFR—brain cancer	9.6e-05	0.000333	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—IL2—brain cancer	9.6e-05	0.000333	CbGpPWpGaD
Sirolimus—MTOR—Disease—IDH1—brain cancer	9.58e-05	0.000332	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—EGFR—brain cancer	9.55e-05	0.000331	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	9.52e-05	0.00033	CbGpPWpGaD
Sirolimus—MTOR—DAP12 signaling—EGFR—brain cancer	9.51e-05	0.00033	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—IRS2—brain cancer	9.46e-05	0.000328	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—SIRT1—brain cancer	9.46e-05	0.000328	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CYP2C9—brain cancer	9.43e-05	0.000327	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—RELA—brain cancer	9.43e-05	0.000327	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—SHH—brain cancer	9.43e-05	0.000327	CbGpPWpGaD
Sirolimus—ABCB1—HIF-1-alpha transcription factor network—VEGFA—brain cancer	9.42e-05	0.000327	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—EGFR—brain cancer	9.37e-05	0.000325	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—SUFU—brain cancer	9.37e-05	0.000325	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—brain cancer	9.34e-05	0.000324	CbGpPWpGaD
Sirolimus—EIF4E—Metabolism of proteins—CTNNB1—brain cancer	9.29e-05	0.000322	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—VAV1—brain cancer	9.28e-05	0.000322	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TRPC6—brain cancer	9.09e-05	0.000315	CbGpPWpGaD
Sirolimus—MTOR—Disease—HEY1—brain cancer	9.08e-05	0.000315	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—GFAP—brain cancer	9.04e-05	0.000313	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—STAT3—brain cancer	9.03e-05	0.000313	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—EGFR—brain cancer	8.95e-05	0.00031	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—EGFR—brain cancer	8.95e-05	0.00031	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—EGFR—brain cancer	8.95e-05	0.00031	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—PTCH1—brain cancer	8.94e-05	0.00031	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—SMO—brain cancer	8.94e-05	0.00031	CbGpPWpGaD
Sirolimus—MTOR—Disease—DLL1—brain cancer	8.9e-05	0.000309	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—EGFR—brain cancer	8.86e-05	0.000307	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—RELA—brain cancer	8.85e-05	0.000307	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—ERBB2—brain cancer	8.79e-05	0.000305	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—EGFR—brain cancer	8.79e-05	0.000305	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—EGFR—brain cancer	8.75e-05	0.000303	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—STAT3—brain cancer	8.72e-05	0.000302	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—brain cancer	8.68e-05	0.000301	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CYP2C9—brain cancer	8.66e-05	0.0003	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—HEY1—brain cancer	8.57e-05	0.000297	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—TP53—brain cancer	8.53e-05	0.000296	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—DLL1—brain cancer	8.4e-05	0.000291	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—HES1—brain cancer	8.36e-05	0.00029	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—PDGFRA—brain cancer	8.33e-05	0.000289	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—EGFR—brain cancer	8.28e-05	0.000287	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—brain cancer	8.27e-05	0.000287	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—EGFR—brain cancer	8.21e-05	0.000285	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—VEGFA—brain cancer	8.16e-05	0.000283	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ABR—brain cancer	8.07e-05	0.00028	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—BSG—brain cancer	8.02e-05	0.000278	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—PDGFRA—brain cancer	8e-05	0.000277	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—HES1—brain cancer	7.98e-05	0.000277	CbGpPWpGaD
Sirolimus—FGF2—Immune System—VAV1—brain cancer	7.98e-05	0.000277	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—PDGFRA—brain cancer	7.96e-05	0.000276	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—brain cancer	7.92e-05	0.000275	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—GLI2—brain cancer	7.8e-05	0.00027	CbGpPWpGaD
Sirolimus—MTOR—Immune System—SKP2—brain cancer	7.77e-05	0.000269	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—RELA—brain cancer	7.7e-05	0.000267	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—ERBB2—brain cancer	7.65e-05	0.000265	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—PDGFRA—brain cancer	7.6e-05	0.000264	CbGpPWpGaD
Sirolimus—MTOR—Disease—ENO2—brain cancer	7.57e-05	0.000262	CbGpPWpGaD
Sirolimus—MTOR—Disease—SHH—brain cancer	7.57e-05	0.000262	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—SPP1—brain cancer	7.38e-05	0.000256	CbGpPWpGaD
Sirolimus—FGF2—Disease—VAV1—brain cancer	7.37e-05	0.000255	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—BSG—brain cancer	7.36e-05	0.000255	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—GLI1—brain cancer	7.33e-05	0.000254	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—IRS2—brain cancer	7.31e-05	0.000253	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—VEGFA—brain cancer	7.22e-05	0.00025	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—brain cancer	7.15e-05	0.000248	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—STAT3—brain cancer	7.15e-05	0.000248	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—SHH—brain cancer	7.14e-05	0.000248	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—NOTCH2—brain cancer	7.14e-05	0.000248	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—RELA—brain cancer	7.12e-05	0.000247	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—ERBB2—brain cancer	7.08e-05	0.000245	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—IRS2—brain cancer	7.02e-05	0.000243	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—IRS2—brain cancer	6.99e-05	0.000242	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—SUFU—brain cancer	6.95e-05	0.000241	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—IDH1—brain cancer	6.9e-05	0.000239	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TRPC6—brain cancer	6.89e-05	0.000239	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—VAV1—brain cancer	6.81e-05	0.000236	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—RELA—brain cancer	6.8e-05	0.000236	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PTCH1—brain cancer	6.77e-05	0.000235	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—SMO—brain cancer	6.77e-05	0.000235	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—ERBB2—brain cancer	6.76e-05	0.000234	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—APC—brain cancer	6.73e-05	0.000233	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—GFAP—brain cancer	6.71e-05	0.000232	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—STAT3—brain cancer	6.7e-05	0.000232	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—CTNNB1—brain cancer	6.69e-05	0.000232	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—IRS2—brain cancer	6.67e-05	0.000231	CbGpPWpGaD
Sirolimus—FGF2—Immune System—PDGFRA—brain cancer	6.54e-05	0.000227	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—RELA—brain cancer	6.53e-05	0.000226	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—ERBB2—brain cancer	6.49e-05	0.000225	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—IL2—brain cancer	6.42e-05	0.000222	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HEY1—brain cancer	6.36e-05	0.00022	CbGpPWpGaD
Sirolimus—FGF2—Disease—HES1—brain cancer	6.34e-05	0.00022	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—IDH1—brain cancer	6.33e-05	0.000219	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CYP2C9—brain cancer	6.26e-05	0.000217	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—DLL1—brain cancer	6.23e-05	0.000216	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—CTNNB1—brain cancer	6.19e-05	0.000215	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—APC—brain cancer	6.17e-05	0.000214	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—EGFR—brain cancer	6.09e-05	0.000211	CbGpPWpGaD
Sirolimus—FGF2—Disease—PDGFRA—brain cancer	6.03e-05	0.000209	CbGpPWpGaD
Sirolimus—MTOR—Immune System—VAV1—brain cancer	5.92e-05	0.000205	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—CTNNB1—brain cancer	5.91e-05	0.000205	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—APC—brain cancer	5.89e-05	0.000204	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—PIK3CG—brain cancer	5.89e-05	0.000204	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—VEGFA—brain cancer	5.89e-05	0.000204	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—HES1—brain cancer	5.86e-05	0.000203	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—STAT3—brain cancer	5.83e-05	0.000202	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IRS2—brain cancer	5.74e-05	0.000199	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—TRPC6—brain cancer	5.62e-05	0.000195	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	5.62e-05	0.000195	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—PDGFRA—brain cancer	5.58e-05	0.000193	CbGpPWpGaD
Sirolimus—MTOR—Disease—VAV1—brain cancer	5.47e-05	0.00019	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—TP53—brain cancer	5.45e-05	0.000189	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ENO2—brain cancer	5.45e-05	0.000189	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—SPP1—brain cancer	5.41e-05	0.000188	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—NOTCH2—brain cancer	5.41e-05	0.000188	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—STAT3—brain cancer	5.4e-05	0.000187	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—BSG—brain cancer	5.32e-05	0.000184	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—EGFR—brain cancer	5.3e-05	0.000184	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—SHH—brain cancer	5.3e-05	0.000184	CbGpPWpGaD
Sirolimus—FGF2—Disease—IRS2—brain cancer	5.3e-05	0.000184	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—brain cancer	5.23e-05	0.000181	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—VAV1—brain cancer	5.16e-05	0.000179	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TRPC6—brain cancer	5.11e-05	0.000177	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—RELA—brain cancer	5.05e-05	0.000175	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PTCH1—brain cancer	5.03e-05	0.000174	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—SMO—brain cancer	5.03e-05	0.000174	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—ERBB2—brain cancer	5.01e-05	0.000174	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ENO2—brain cancer	5e-05	0.000173	CbGpPWpGaD
Sirolimus—EIF4E—Gene Expression—MYC—brain cancer	4.99e-05	0.000173	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—EGFR—brain cancer	4.91e-05	0.00017	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IRS2—brain cancer	4.9e-05	0.00017	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PDGFRA—brain cancer	4.85e-05	0.000168	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—RELA—brain cancer	4.85e-05	0.000168	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—ERBB2—brain cancer	4.81e-05	0.000167	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—ERBB2—brain cancer	4.79e-05	0.000166	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYP2C9—brain cancer	4.72e-05	0.000164	CbGpPWpGaD
Sirolimus—MTOR—Disease—HES1—brain cancer	4.7e-05	0.000163	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—EGFR—brain cancer	4.68e-05	0.000162	CbGpPWpGaD
Sirolimus—FGF2—Disease—APC—brain cancer	4.68e-05	0.000162	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—brain cancer	4.62e-05	0.00016	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—RELA—brain cancer	4.61e-05	0.00016	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—ERBB2—brain cancer	4.58e-05	0.000159	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—IDH1—brain cancer	4.58e-05	0.000159	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—brain cancer	4.57e-05	0.000159	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—EGFR—brain cancer	4.5e-05	0.000156	CbGpPWpGaD
Sirolimus—MTOR—Disease—PDGFRA—brain cancer	4.48e-05	0.000155	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—HES1—brain cancer	4.44e-05	0.000154	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—CTNNB1—brain cancer	4.39e-05	0.000152	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—APC—brain cancer	4.32e-05	0.00015	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—PIK3CG—brain cancer	4.32e-05	0.00015	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IRS2—brain cancer	4.26e-05	0.000148	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PDGFRA—brain cancer	4.23e-05	0.000147	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—CTNNB1—brain cancer	4.19e-05	0.000145	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—IL2—brain cancer	4.15e-05	0.000144	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—SPP1—brain cancer	4.1e-05	0.000142	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CCND1—brain cancer	4.04e-05	0.00014	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—brain cancer	4.03e-05	0.00014	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NOTCH2—brain cancer	4.02e-05	0.000139	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—BSG—brain cancer	4.02e-05	0.000139	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CTNNB1—brain cancer	4e-05	0.000139	CbGpPWpGaD
Sirolimus—FGF2—Immune System—RELA—brain cancer	3.96e-05	0.000137	CbGpPWpGaD
Sirolimus—FGF2—Immune System—ERBB2—brain cancer	3.94e-05	0.000136	CbGpPWpGaD
Sirolimus—MTOR—Disease—IRS2—brain cancer	3.93e-05	0.000136	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—VAV1—brain cancer	3.83e-05	0.000133	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IRS2—brain cancer	3.71e-05	0.000129	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—brain cancer	3.7e-05	0.000128	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—STAT3—brain cancer	3.66e-05	0.000127	CbGpPWpGaD
Sirolimus—FGF2—Disease—ERBB2—brain cancer	3.63e-05	0.000126	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—brain cancer	3.62e-05	0.000126	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ENO2—brain cancer	3.62e-05	0.000125	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IL2—brain cancer	3.57e-05	0.000124	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—VEGFA—brain cancer	3.53e-05	0.000122	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—STAT3—brain cancer	3.49e-05	0.000121	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—EGFR—brain cancer	3.48e-05	0.00012	CbGpPWpGaD
Sirolimus—MTOR—Disease—APC—brain cancer	3.47e-05	0.00012	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—IDH1—brain cancer	3.45e-05	0.00012	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CTNNB1—brain cancer	3.44e-05	0.000119	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—MYC—brain cancer	3.4e-05	0.000118	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—RELA—brain cancer	3.38e-05	0.000117	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—ERBB2—brain cancer	3.36e-05	0.000116	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—EGFR—brain cancer	3.34e-05	0.000116	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—EGFR—brain cancer	3.32e-05	0.000115	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HES1—brain cancer	3.29e-05	0.000114	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PIK3CG—brain cancer	3.28e-05	0.000114	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—APC—brain cancer	3.28e-05	0.000114	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MYC—brain cancer	3.24e-05	0.000112	CbGpPWpGaD
Sirolimus—FGF2—Disease—CTNNB1—brain cancer	3.18e-05	0.00011	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—EGFR—brain cancer	3.17e-05	0.00011	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PDGFRA—brain cancer	3.14e-05	0.000109	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—SPP1—brain cancer	3.04e-05	0.000106	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IL2—brain cancer	3.04e-05	0.000105	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	3.04e-05	0.000105	CbGpPWpGaD
Sirolimus—FGF2—Immune System—STAT3—brain cancer	3e-05	0.000104	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CCND1—brain cancer	2.97e-05	0.000103	CbGpPWpGaD
Sirolimus—MTOR—Immune System—RELA—brain cancer	2.94e-05	0.000102	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CTNNB1—brain cancer	2.94e-05	0.000102	CbGpPWpGaD
Sirolimus—MTOR—Immune System—ERBB2—brain cancer	2.92e-05	0.000101	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYP2C9—brain cancer	2.91e-05	0.000101	CbGpPWpGaD
Sirolimus—FGF2—Disease—STAT3—brain cancer	2.77e-05	9.61e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IRS2—brain cancer	2.75e-05	9.55e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ENO2—brain cancer	2.73e-05	9.46e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—EGFR—brain cancer	2.73e-05	9.46e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—ERBB2—brain cancer	2.7e-05	9.35e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TP53—brain cancer	2.66e-05	9.23e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL2—brain cancer	2.65e-05	9.18e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—VEGFA—brain cancer	2.59e-05	8.96e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—MYC—brain cancer	2.57e-05	8.93e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—RELA—brain cancer	2.56e-05	8.88e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—STAT3—brain cancer	2.56e-05	8.88e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CTNNB1—brain cancer	2.56e-05	8.86e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—ERBB2—brain cancer	2.54e-05	8.82e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—EGFR—brain cancer	2.52e-05	8.73e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PIK3CG—brain cancer	2.5e-05	8.67e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—BSG—brain cancer	2.47e-05	8.58e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—APC—brain cancer	2.43e-05	8.43e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PIK3CG—brain cancer	2.43e-05	8.43e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MYC—brain cancer	2.38e-05	8.25e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—CTNNB1—brain cancer	2.36e-05	8.18e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—EGFR—brain cancer	2.33e-05	8.07e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IL2—brain cancer	2.31e-05	7.99e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PIK3CG—brain cancer	2.3e-05	7.96e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CCND1—brain cancer	2.25e-05	7.79e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—STAT3—brain cancer	2.23e-05	7.72e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CTNNB1—brain cancer	2.23e-05	7.72e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—IDH1—brain cancer	2.13e-05	7.37e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—STAT3—brain cancer	2.06e-05	7.13e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—EGFR—brain cancer	2.02e-05	7.02e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—VEGFA—brain cancer	1.96e-05	6.79e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TP53—brain cancer	1.95e-05	6.77e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—STAT3—brain cancer	1.94e-05	6.73e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—MYC—brain cancer	1.91e-05	6.62e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—RELA—brain cancer	1.9e-05	6.59e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ERBB2—brain cancer	1.89e-05	6.55e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—EGFR—brain cancer	1.87e-05	6.48e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MYC—brain cancer	1.8e-05	6.25e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—EGFR—brain cancer	1.76e-05	6.11e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL2—brain cancer	1.71e-05	5.93e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ENO2—brain cancer	1.68e-05	5.83e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCND1—brain cancer	1.67e-05	5.78e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PIK3CG—brain cancer	1.66e-05	5.75e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CTNNB1—brain cancer	1.65e-05	5.73e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TP53—brain cancer	1.48e-05	5.13e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—VEGFA—brain cancer	1.45e-05	5.04e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—STAT3—brain cancer	1.44e-05	4.99e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MYC—brain cancer	1.34e-05	4.64e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—EGFR—brain cancer	1.31e-05	4.54e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PIK3CG—brain cancer	1.25e-05	4.34e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TP53—brain cancer	1.1e-05	3.81e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PIK3CG—brain cancer	7.71e-06	2.67e-05	CbGpPWpGaD
